Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation
Sponsor: Vivalyx GmbH • ClinicalTrials.gov ID: NCT07792317
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors. Preservation of DCD organs using the current clinically applied preservation solutions is associated with up to 73% incidence of delayed graft function, highlighting the need for new preservation solutions designed to improve early graft function. Omnisol is expected to result in equivalent or improved kidney preservation as compared to currently marketed organ preservation solutions used for HMP.
Interventions
-
Omnisol organ preservation solution
(Device)
Omnisol for HMP of deceased donor kidneys
Eligibility criteria
Conditions
Locations
- Erasmus Medical Center — Rotterdam, Netherlands
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record